The immune response to pneumococcal vaccination in patients after community acquired pneumonia with S. pneumoniae is different compared to pneumonia patients with another pathogen.
ID
Bron
Verkorte titel
Aandoening
immune respons
pneumococcal vaccination
pneumococcal conjugate vaccination
PCV13
pneumonia
Ondersteuning
Onderzoeksproduct en/of interventie
Uitkomstmaten
Primaire uitkomstmaten
Immune response to pneumococcal vaccination in patients who were diagnosed with CAP due to S. pneumoniae in comparison with patients with another causative pathogen. Main parameters are antibody titres against the different
pneumococcal serotypes before and after vaccination and avidity maturation of these antibodies.
Achtergrond van het onderzoek
NA
Doel van het onderzoek
The immune response to pneumococcal vaccination in patients after community acquired
pneumonia with S. pneumoniae is different compared to pneumonia patients with another pathogen.
Onderzoeksopzet
1) Week 1, first blood draw, vaccination, RAND36.
2) After 3-4 weeks, second blood draw.
Onderzoeksproduct en/of interventie
13-valent pneumococcal conjugate vaccination, prevenar 13 (PCV13)
Algemeen / deelnemers
G. Wagenvoort
Nieuwegein 3435 CM
The Netherlands
0883203000
g.wagenvoort@antoniusziekenhuis.nl
Wetenschappers
G. Wagenvoort
Nieuwegein 3435 CM
The Netherlands
0883203000
g.wagenvoort@antoniusziekenhuis.nl
Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)
1. Patients who participated in the Ovidius or Triple-P study (2004-2009).
2. Diagnosis in these studies with pneumococcal pneumonia or pneumonia due another identified organism.
3. Age > 18 years.
4. Signing of informed consent.
Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)
Changed 2-sep-2014:
1. Diagnosis of pneumonia without an identified causative organism.
2. Fever at time of vaccination.
3. Previous/known allergic reaction to any of the components of the vaccine given.
4. Mentally incompetent.
5. Previous pneumococcal conjugate vaccination.
6. Pneumococcal polysaccharide vaccination within 6 months prior to inclusion.
7. Clinical pneumonia within 1 month prior to inclusion.
Opzet
Deelname
Voornemen beschikbaar stellen Individuele Patiënten Data (IPD)
Opgevolgd door onderstaande (mogelijk meer actuele) registratie
Andere (mogelijk minder actuele) registraties in dit register
Geen registraties gevonden.
In overige registers
| Register | ID |
|---|---|
| NTR-new | NL4221 |
| NTR-old | NTR4460 |
| CCMO | NL44924.100.13 |
| OMON | NL-OMON40285 |